Unfortunately, post-BRAFi lesions were not sufficiently represented in the patient cohort that we had available to allow us to reliably assess the prevalence of EGFR expression on tumor tissues following gain of BRAFi-resistance. The gene discussed is EGFR; the disease is neoplasm.